Bellberry Ethics Approval Activates New HARNESS Trial Sites
Filed with ASX · · 3 pages · English
Story so far
Earlier from Racura Oncology
- Racura Oncology Doses First Patient in Phase 1 HARNESS-1 Trial of RC220 in EGFR-Mutant Non-Small Cell Lung Cancer
- Racura Treats First Patient in HARNESS-1 Lung Cancer Trial
- Racura raised $34.3m to Advance Three Oncology Trials
- Emerging Companies Specialist Invests in Racura
- Racura Enters Underwriting Agreement for Options
Later from Racura Oncology
- June 2026 Quarterly Activities Report and Appendix 4C
- Racure Oncology Techknow Invest Presentation
- First HARNESS-1 Patient Safely Treated with RC220
- Appendix 4E & Annual Report
- Appendix 4G
Follow Racura Oncology into a list and get an email when it puts out news.
Follow Racura Oncology